MedTrace Logo

BB-10901 in Treating Patients With Relapsed and/or Refractory Multiple Myeloma

NCT00346255 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 37

Last updated 2013-04-23

No results posted yet for this study

Summary

RATIONALE: Monoclonal antibodies, such as BB-10901, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them.

PURPOSE: This phase I trial is studying the side effects and best dose of BB-10901 in treating patients with relapsed and/or refractory multiple myeloma.

Conditions

Interventions

DRUG

BB-10901

dose escalation study, doses will vary per cohort. patients will receive an IV infusion weekly for two weeks every three weeks.

Sponsors & Collaborators

  • ImmunoGen, Inc.

    lead INDUSTRY

Principal Investigators

  • Asher Alban Akmal Chanan-Khan,, M.D. · Roswell Park Cancer Institute

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-04-30
Primary Completion
2011-03-31
Completion
2011-03-31

Countries

  • United States
  • Argentina

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00346255 on ClinicalTrials.gov